Literature DB >> 21665222

Population pharmacokinetics of pentobarbital in neonates, infants, and children after open heart surgery.

Athena F Zuppa1, Susan C Nicolson, Jeffrey S Barrett, Marc R Gastonguay.   

Abstract

OBJECTIVES: To determine the pharmacokinetics of pentobarbital in neonates, infants, and young children with congenital heart disease after open-heart surgery. STUDY
DESIGN: Thirty-five subjects (3.0 days-4.4 years) after open-heart surgery who received pentobarbital as standard of care were enrolled. Serial pharmacokinetic blood samples were obtained. A population-based, nonlinear mixed-effects modeling approach was used to characterize pentobarbital pharmacokinetics.
RESULTS: A two-compartment model with weight as a co-variate allometrically expressed on clearance (CL), inter-compartmental clearance, central (V1) and peripheral volume of distributions, bypass grafting time as a co-variate on CL and V1, and age and ventricular physiology as co-variates on CL best described the pharmacokinetics. A typical infant (two-ventricle physiology, 6.9 kg, 5.2 months, and bypass grafting time of 60 minutes) had a CL of 0.12 L/hr/kg, V1 of 0.45 L/kg, and peripheral volume of distributions of 0.98 L/kg. The bypass grafting effect was poorly estimated. For subjects <12 months age, an age effect on CL remained after accounting for weight and was precisely estimated.
CONCLUSIONS: Pentobarbital pharmacokinetics is influenced by age and weight. Subjects with single-ventricle physiology demonstrated a 15% decrease in clearance when compared with subjects with two-ventricle physiology.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21665222      PMCID: PMC3157563          DOI: 10.1016/j.jpeds.2011.04.021

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  14 in total

1.  Initial experience with intravenous pentobarbital sedation for children undergoing MRI at a tertiary care pediatric hospital: the learning curve.

Authors:  S B Greenberg; R C Adams; C L Aspinall
Journal:  Pediatr Radiol       Date:  2000-10

2.  Population pharmacokinetic analysis of varenicline in adult smokers.

Authors:  Patanjali Ravva; Marc R Gastonguay; Thomas G Tensfeldt; Hélène M Faessel
Journal:  Br J Clin Pharmacol       Date:  2009-11       Impact factor: 4.335

3.  Pharmacokinetics and distribution properties of pentobarbital in humans following oral and intravenous administration.

Authors:  M Ehrnebo
Journal:  J Pharm Sci       Date:  1974-07       Impact factor: 3.534

4.  IV Nembutal: safe sedation for children undergoing CT.

Authors:  J D Strain; J B Campbell; L A Harvey; L C Foley
Journal:  AJR Am J Roentgenol       Date:  1988-11       Impact factor: 3.959

5.  Comparison of oral pentobarbital sodium (nembutal) and oral chloral hydrate for sedation of infants during radiologic imaging: preliminary results.

Authors:  Veronica J Rooks; Taylor Chung; Linda Connor; David Zurakowski; Frederic A Hoffer; Keira P Mason; Patricia E Burrows
Journal:  AJR Am J Roentgenol       Date:  2003-04       Impact factor: 3.959

6.  Intravenously administered pentobarbital sodium for sedation in pediatric CT.

Authors:  J D Strain; L A Harvey; L C Foley; J B Campbell
Journal:  Radiology       Date:  1986-10       Impact factor: 11.105

7.  Pharmacokinetics of high-dose pentobarbital in severe head trauma.

Authors:  C D Bayliff; M L Schwartz; B G Hardy
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

8.  Etomidate versus pentobarbital for sedation of children for head and neck CT imaging.

Authors:  Andrew J Kienstra; Mark A Ward; Fahimeh Sasan; Jill Hunter; M Craig Morriss; Charles G Macias
Journal:  Pediatr Emerg Care       Date:  2004-08       Impact factor: 1.454

9.  High-dose pentobarbital pharmacokinetics in hypothermic brain-injured children.

Authors:  D H Schaible; G C Cupit; D B Swedlow; M L Rocci
Journal:  J Pediatr       Date:  1982-04       Impact factor: 4.406

10.  Pentobarbital pharmacokinetics in patients with severe head injury.

Authors:  D P Wermeling; R A Blouin; W H Porter; R P Rapp; P A Tibbs
Journal:  Drug Intell Clin Pharm       Date:  1987-05
View more
  5 in total

1.  Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children.

Authors:  Chiara Piana; Wei Zhao; Kimberly Adkison; David Burger; Evelyne Jacqz-Aigrain; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

Review 2.  Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group.

Authors:  Susan M Abdel-Rahman; Gordon L Amidon; Ajay Kaul; Viera Lukacova; Alexander A Vinks; Gregory T Knipp
Journal:  Clin Ther       Date:  2012-11       Impact factor: 3.393

3.  Evaluation and optimisation of current milrinone prescribing for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgery using a physiology-based pharmacokinetic drug-disease model.

Authors:  Winnie Vogt
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

4.  Stability of Pentobarbital Hydrogel for Rectal Administration in Pediatric Procedural Sedation.

Authors:  Sephora Belo; Justine Touchard; Philippe-Henri Secretan; Fabrice Vidal; Vincent Boudy; Salvatore Cisternino; Joël Schlatter
Journal:  Hosp Pharm       Date:  2020-01-22

5.  Population pharmacokinetics of piperacillin/tazobactam in neonates and young infants.

Authors:  Zhiping Li; Yewei Chen; Qin Li; Di Cao; Wenjing Shi; Yun Cao; Dan Wu; Yiqing Zhu; Yi Wang; Chao Chen
Journal:  Eur J Clin Pharmacol       Date:  2013-01-26       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.